Long COVID Research and Breakthroughs with Julia Moore Vogel, PhD, MBA

Published on: 

Strategic Alliance Partnership | <b>American Lung Association</b>

In the latest Lungcast, a nationally-leading researcher and long COVID patient discusses what's known and unknown about the chronic viral syndrome.

As COVID-19 continues toward ia stage post-global health crisis status, health care is increasingly challenged by the long-term impact of the pandemic virus on patients. Long COVID, once case study fodder at the height of the global outbreak, is now understood to be a highly prevalent and uniquely burdensome disease in a portion of patients previously infected with SARS-CoV-2.

As cases increase significantly, clinicians and researchers are continuing to seek answers on its characteristics. What drives the disease? What are quantifiable symptoms? Who is at greatest risk?

A handful of investigators are making headway on these clinical pursuits. One such expert spoke with Lungcast for its July 2023 episode.

Julia Moore Vogel, PhD, MBA, program director of The Participant Center at Scripps’ All of Us Research Program, joins to discuss her professional ventures into Long COVID research—as well as her own personal experiences as a patient with the disease.

In her conversation with American Lung Association (ALA) chief medical officer Al Rizzo, MD, Moore Vogel reviews the status of a litany of topics surrounding Long COVID epidemiology and pathophysiology. Among the key subjects are a dive into its pediatric impacts, the pursuit of biomarkers and indicators of disease, and her own work into public awareness, education and adequate resourcing.

Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.

Subscribe to Lungcast on Spotify here or listen to the latest episode below: